drugset / Trial / NCT00674752

A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia

NCT00674752 ↗

Phase 3 Completed 377 enrolled Viatris Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the effect of gabapentin on polysomnographic assessments in transient insomnia induced by a sleep phase advance.

Timeline

Start
2006-03
Primary completion
—
Completion
2006-08

Outcome

Met primary endpoint

paper wake after sleep onset (primary endpoint) (135.7 [placebo], 100.7 [250 mg], and 73.2 [500 mg] min) was significantly lower PMID 25317090 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Unknown 250 mg Oral
Subject Gabapentin Unknown 500 mg Oral

Indications